Winton Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Winton Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,446	Closed	-$528K	–	1363
2025 Q4	$528K	Buy	+6,446	New	+$481K	0.02%	624

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Winton Group's TARS Position: Q1 2026 in Review

Winton Group sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 6,446 shares — an estimated $528K sold.

Winton Group first reported a position in TARS in Q4 2025 and held it in 1 quarter. The position peaked at $528K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Winton Group reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Winton Group sold 6,446 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $528K.
Winton Group first reported a position in Tarsus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Winton Group's Tarsus Pharmaceuticals position peaked at $528K in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.